Home Multimedia Podcasts Drug Repositioning as a Viable Business Model Drug Repositioning as a Viable Business Model March 10, 2011 Aris Persidis, Ph.D., President, Biovista /wp-content/uploads/2018/09/gencast_030911.mp3 PodcastsResourcesBusiness ethicDrugsEthicsEthics, law and policyPharmacology Also of Interest Rising from the Ashes: FDA Grants EUA to Invivyd COVID-19 Antibody Novo Nordisk to Acquire Cardior for Up to $1.1B, Boosting Cardiovascular Pipeline StockWatch: CDMOs Tumble as Congress Takes Aim at Chinese Biotechs Lonza to Buy Genentech's Vacaville, CA Biologics Manufacturing Site for $1.2B 10x Defends Patent Litigation Strategy after Criticism from Researchers, Rivals Alexandria Founder Talks Takeda, Massachusetts, NYC, and 30th Anniversary Related Media BIO CEO Rachel King Outlines Industry's Challenges on "Close to the Edge" Emerging Markets Collaborate to Succeed in Post-Pandemic World Book Review: The Exceptions Global Single-Use Network Support Assurance of Supply Resins Address Downstream Purification Concerns Materials Sourcing: Precautions and Improvements for Cell and Gene Therapies Related Content Rising from the Ashes: FDA Grants EUA to Invivyd COVID-19 Antibody Novo Nordisk to Acquire Cardior for Up to $1.1B, Boosting Cardiovascular Pipeline StockWatch: CDMOs Tumble as Congress Takes Aim at Chinese Biotechs Lonza to Buy Genentech’s Vacaville, CA Biologics Manufacturing Site for $1.2B